Media Articles Related to Priftin (Rifapentine)
Tuberculosis Pathogen Proteome Atlas
Source: Health News from Medical News Today [2013.05.17]
Photographers know the problem all too well: with the naked eye, you can see which branch a bird is sitting on, but spotting the bird in the blur of branches through the telephoto lens for high-magnification images requires considerable skill. It is a similar story for researchers who are looking to study proteins, the active biomolecules of cells. Olga Schubert, a doctoral student at ETH Zurich's Institute for Molecular Systems Biology, and her colleagues have now come up with a search aid...
Rapid, Accurate Diagnosis Of Tuberculosis And Other Bacterial Infections Using Portable Device
Source: Medical Devices / Diagnostics News From Medical News Today [2013.05.08]
A handheld diagnostic device that Massachusetts General Hospital (MGH) investigators first developed to diagnose cancer has been adapted to rapidly diagnose tuberculosis (TB) and other important infectious bacteria...
'Alarming' Rise Seen in Drug-Resistant Tuberculosis
Source: MedicineNet Tuberculosis Specialty [2012.08.31]
Title: 'Alarming' Rise Seen in Drug-Resistant Tuberculosis
Category: Health News
Created: 8/30/2012 2:05:00 PM
Last Editorial Review: 8/31/2012 12:00:00 AM
Source: MedicineNet Neutropenia Specialty [2011.07.22]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/22/2011 12:00:00 AM
A Step Closer To Understanding Why Antibiotics Are Ineffective Against Certain Types Of Bacteria
Source: MRSA / Drug Resistance News From Medical News Today [2013.04.26]
Antibiotic resistance is a global problem. The World Health Organisation (WHO) estimates that for tuberculosis alone multi-drug resistance accounts for more than 150,000 deaths each year. WHO warns of "a doomsday scenario of a world without antibiotics," in which antibiotic resistance will turn common infections into incurable killers and make routine surgeries a high-risk gamble...
Published Studies Related to Priftin (Rifapentine)
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. [2006.04.15]
RATIONALE: Treatment of latent tuberculosis (TB) infection with weekly rifapentine and isoniazid is a potentially effective alternative to current therapies. OBJECTIVES: To compare the efficacy of weekly rifapentine/isoniazid to daily rifampin/pyrazinamide in preventing TB in household contacts of patients with pulmonary TB in Brazil... CONCLUSIONS: Rifapentine/isoniazid was better tolerated than rifampin/pyrazinamide and was associated with good protection against TB. Rifapentine/isoniazid weekly for 12 wk is likely a promising therapy for latent TB infection.
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. [2004.06.01]
The pharmacokinetics of rifapentine at 600, 900, and 1,200 mg were studied during once-weekly continuation phase therapy in 35 patients with tuberculosis. Mean area under the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.hour/ml at 600, 900, and 1,200 mg, respectively; p = 0.02 by linear regression).
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. [2003.05.15]
To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective than twice-weekly isoniazid/rifampin, we studied human immunodeficiency virus-seronegative patients with either failure (n = 4), relapse (n = 35), or cure (n = 94), recruited from a comparative treatment trial...
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. [2002.06.01]
Once-weekly rifapentine 600 mg plus isoniazid (INH) during the continuation phase treatment of tuberculosis is associated with a relapse rate higher than that of twice-weekly rifampin plus INH... Further evaluation of the safety and tolerability of rifapentine 1,200 mg is warranted.
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. [2002.01]
SETTING: Clinical trial in 672 patients with newly diagnosed pulmonary tuberculosis in Hong Kong. After an initial 2 months of a four-drug intensive phase consisting of thrice-weekly streptomycin, isoniazid, rifampicin and pyrazinamide (SHRZ), a random allocation was made to a continuation phase of once-weekly 600 mg rifapentine + 15 mg/kg isoniazid (HRp1), HRp1 given in 2 of every 3 weeks (HRp1.2/3), or to thrice-weekly isoniazid + rifampicin (HR3), the standard treatment in Hong Kong. OBJECTIVE: Final report evaluating adverse events (46 relapses and one failure) after 5 years and the prognostic influence of various factors... CONCLUSIONS: The two rifapentine regimens were unsatisfactory because of their high incidence of adverse events. Isoniazid appeared not to contribute to preventing relapse. Further studies with increased rifapentine dosage are necessary.
Clinical Trials Related to Priftin (Rifapentine)
Study of Daily Rifapentine for Pulmonary Tuberculosis [Recruiting]
The goal of this Phase 2 study is to determine the microbiological activity and safety of
rifapentine when given as a component of multidrug intensive phase treatment of
smear-positive pulmonary TB.
The Effect of Rifapentine on Raltegravir [Recruiting]
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers [Recruiting]
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine [Completed]
Primary objective: To compare the pharmacokinetics of rifapentine and 25-desacetyl
rifapentine at three different doses: 600 mg, 900 mg, and 1200 mg.
Secondary objective: To describe any correlation between pharmacokinetic parameters of three
different doses of rifapentine plus a standard dose of isoniazid and the occurrence of
toxicity attributed to anti-tuberculosis treatment.
Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis [Recruiting]
Although effective therapy for tuberculosis is available, TB continues to cause significant
problems worldwide, and rates of multi-drug resistant (MDR) TB cases are on the rise. A
major obstacle to the control of TB is poor adherence with lengthy (usually 6 months) and
complicated treatment regimens. Incomplete TB treatment can lead to serious consequences
such as increased severity of illness and death, prolonged infectiousness and transmission
in the community, and the development of drug resistance. The development of new treatment
strategies with more stronger drugs could lead to shorter and simpler regimens. A TB
treatment regimen that allowed treatment duration to be meaningfully decreased would have
important public health implications.
This trial will compare the effect and safety of a new oral regimen to that of the standard
regimen for the first phase of treatment for pulmonary tuberculosis.
The experimental regimen will consist of the following:
- Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered
once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
The standard control intensive phase regimen will consist of the following:
- Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered
once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
Following intensive phase therapy (the study phase), all patients will be treated with a
non-experimental continuation phase regimen.
In mice, the combination of Moxifloxacin and Rifapentine have cured the animals
significantly faster than the standard regimen and this study will be the first step to see
if the potential is also there in humans.